Fertility clinics push back
By Alison Motluk,
HeyReprotech Newsletter
| 04. 21. 2020
Advisory bodies generally agree that now is not the time for full-on fertility treatment. Some prominent clinics beg to differ.
Several of the fertility world's top advisory bodies have strongly urged fertility clinics to stop or severely scale back services during the COVID-19 pandemic.
The European Society of Human Reproduction and Embryology (ESHRE) last week reaffirmed that fertility doctors, like other medical professionals, have a "duty" to not make this crisis worse and so should not be providing non-urgent services. Only people facing cancer treatment should be exceptions, they advised.
They underscored the reasons for their decision: to avoid any coronavirus-related pregnancy complications, to mitigate the unknown risks of parent-to-child transmission, to keep medical resources on the front lines and to follow the rules on physical distancing.
The American Society for Reproductive Medicine (ASRM) first issued guidelines about COVID-19 on March 17 and have since provided two updates. In the most recent, on April 14, they advised that "it is not yet prudent to resume non-emergency infertility procedures." They said that clinics should avoid starting new treatment cycles, cancel all transfers, suspend non-urgent procedures and minimize in-person interactions. The Canadian Fertility and Andrology Society (CFAS) has been advocating...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...